Posts by MacD


HomeMacD

DCprime Extends International Roll-out of DCP-001 Into the United States

Opening of IND follows approval to study DCP-001 in multiple European countries Leiden, The Netherlands, May 13, 2020 –DCprime, the front-runner in the field of relapse vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for DCP-001, an allogeneic cancer relapse vaccine currently being


DCprime Receives US FDA Orphan Drug Designation for DCP-001 in Acute Myeloid Leukemia

Leiden, The Netherlands, December 05, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCP-001 for the treatment of acute myeloid leukemia (AML). DCP-001 is a cell-based vaccine addressing blood cancers with a high risk of relapse


DCprime to Present Long-term Follow-up and Survival Data for Lead Relapse Vaccine Candidate DCP-001 in High-Risk AML and MDS Patients

Presentation at ASH Annual Meeting Shows Potential to Prolong Relapse-Free Survival and Overall Survival Using an Allogeneic Cell-based Vaccine in the Post-Remission Setting   Leiden, The Netherlands, November 13, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of updated clinical results for its lead product DCP-001 at the upcoming